Business

Engage Therapeutics has closed a $23 million Series A financing round led by TPG Biotech that will fund a Phase 2b clinical trial of an inhaled alprazolam for the treatment of acute epileptic seizures. Alexza Pharmaceuticals, which has developed the Staccato alprazolam through Phase 2a, registered the trademark for Engage Therapeutics in 2015. According to one … [Read more...] about Engage Therapeutics closes $23 million series A financing round to fund development of inhaled alprazolam

Galen US has acquired US rights to Alexza Pharmaceuticals' Adasuve inhaled loxapine for the treatment of agitation in patients with schizophrenia or bipolar I. Adasuve was approved by the FDA in December 2012 for use in certain healthcare facilities enrolled in the Adasuve REMS program only. In May 2013, Teva announced that it had acquired US rights to Adasuve, and … [Read more...] about Galen acquires US rights to Adasuve inhaled loxapine

4D Molecular Therapeutics (4DMT) has received $3 million from Cystic Fibrosis Foundation Therapeutics (CFFT) for development of 4D-710, an aerosolized adeno-associated virus (AAV) gene therapy vector that will deliver a functional copy of the CFTR gene to the lungs of CF patients, the company said. The funding will be used for completion of studies to support an … [Read more...] about 4D Molecular Therapeutics gets $3 million from CFFT for development of aerosol gene therapy

The US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has awarded a grant worth up to $63 million to Emergent BioSolutions for development of a single-use stabilized isoamyl nitrite (SIAN) nasal spray for the treatment of acute cyanide poisoning. The initial 17-month, $12.7 million agreement will cover … [Read more...] about Emergent BioSolutions gets BARDA grant worth up to $63 million for development of intranasal cyanide antidote

Insmed has closed a public offering of common stock that generated net proceeds of ~$377.7 million, the company said. The proceeds will be used in large part for continued development, regulatory submissions, and potential commercialization of ALIS amicakin liposome inhalation suspension. According to the announcement, planned uses for the proceeds include "invest … [Read more...] about Insmed public offering nets over $377 million

Pulmatrix has announced a licensing agreement with Vectura for US development of Pulmatrix's PUR0200 dry powder tiotropium formulation for the treatment of COPD. Vectura will pay Pulmatrix a $1 million "technology access fee" on achievement of certain milestones and will take responsibility for US development beginning immediately. According its own announcement, … [Read more...] about Pulmatrix licenses PUR0200 dry powder tiotropium to Vectura

According to Pulmatrix, the Cystic Fibrosis Foundation Therapeutics (CFFT) will provide funds to support non-clinical development of PUR1900, an itraconazole DPI, for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis and asthma patients. The amount of the award was not specified by Pulmatrix; however, the CFFT website says that … [Read more...] about Pulmatrix gets development award from Cystic Fibrosis Foundation Therapeutics for PUR1900

Ascend Therapeutics is now promoting Egalet's Sprix ketorolac tromethamine nasal spray for the treatment of moderate-to-moderately severe pain to women's healthcare providers in the US, Egalet said. According to Egalet, the companies signed the agreement allowing Ascend to promote the product in July 2017. Egalet Chief Commercial Officer Patrick Shea commented, … [Read more...] about Ascend Therapeutics now promoting Egalet’s Sprix nasal spray in the US

Dance Biopharm announced that it has bought back the Asia license for its Dance-501 soft mist inhaled insulin by purchasing the license holder, Harmony Biopharm Limited, from Harmony Plus Holdings Limited (Harmony). Dance said that Harmony will receive stock and a percentage of future sales of the product in China and that Harmony will continue to advise Dance on … [Read more...] about Dance Biopharm buys back Asia license for Dance-501 inhaled insulin